申请人:Pfizer Inc.
公开号:US05665749A1
公开(公告)日:1997-09-09
This invention relates to new heterocyclic compounds which are selective inhibitors of 5-lipoxygenase (5-LO). The new heterocyclic compounds are useful in inhibiting 5-LO per se and in the treatment or alleviation of inflammatory disease or condition, allergy or cardiovascular diseases in mammals wherein the inflammatory disease or condition includes but is not limited to asthma, arthritis, bronchi chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis, shock, atopic dermatitis, rheumatoid arthritis or osteoa This invention also relates to pharmaceutical compositions useful therefor.
这项发明涉及新的杂环化合物,这些化合物是5-脂氧合酶(5-LO)的选择性抑制剂。这些新的杂环化合物在抑制5-LO本身以及在哺乳动物中治疗或缓解炎症性疾病或症状、过敏或心血管疾病方面是有用的,其中炎症性疾病或症状包括但不限于哮喘、关节炎、慢性阻塞性肺病、牛皮癣、过敏性鼻炎、皮炎、休克、特应性皮炎、类风湿关节炎或骨关节炎。这项发明还涉及用于这些用途的药物组合物。